Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06395948Phase 2Active Not Recruiting

A Study Evaluating APG777 in Atopic Dermatitis

Role: lead

NCT07003425Phase 2Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Role: lead

NCT07027527Phase 1Active Not Recruiting

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT06920901Phase 1Active Not Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

Role: lead

All 4 trials loaded